THC Global Group issued its quarterly update for the period ended on September 30, 2019.
THC Global Group (ASX:THC) issued its quarterly update for the period ended on September 30, 2019.
As quoted in the press release:
Australian Cannabis Operations: Licenced Farm to Pharma
THC Global has secured Schedule 8 Controlled Substance (S8) and Schedule 4 Prescription Medicine (S4) Manufacturing and Wholesale Licences from the Queensland Department of Health for both the Company’s Southport Manufacturing Facility and its ‘Bundy’ Facility. These licences enable THC Global to hold, manufacture, and wholesale S8 and S4 substances and medicines including medicinal cannabis. These licences were a key requirement for the commencement of Australian supply and distribution of THC Global’s Australian produced medicinal cannabis as both S8 controlled medicines and S4 pharmacy medicines.
New Zealand CBD Products Sales: Shipment Sold Out
THC Global is the exclusive distributor of cannabidiol (CBD) products produced by Endoca, a European cannabis producer, in New Zealand. In support of the Company’s distribution activities of CBD products, the Company provided financial assistance to DATAPHARM, a healthcare company in New Zealand, to launch CBDinfo.co.nz (CBDinfo).